Reports
Cost of Inaction in Treating Obesity in Australia
card, titleone-fs-32px, description-fs-20px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-general-third-parties, ctaselection-link-two, ctatarget-newtab-two, ctaexitinterstitial-general-third-parties-two, ctanumber-two
This independent report from GlobalData and funded by Eli Lilly Australia, reveals obesity and overweight are quietly draining US$123 million from Australia's economy every day – US$45 billion annually. While the debate about action on obesity continues, Australians, our healthcare system, and businesses are already paying a high price. This analysis provides undeniable evidence to underpin targeted policy interventions.
2025 Year in Review
card, titleone-fs-32px, description-fs-20px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-outside-country, ctatarget-sametab-two, ctaexitinterstitial-select-two, ctanumber-one
2025 was an important year for Lilly and for the patients we serve. We advanced exciting scientific research and expanded access to our innovative medicines, growing our impact and our capacity to serve more patients worldwide.
Let’s Talk About Weight: A national report on lived experiences of obesity and weight management in Australia
card, titleone-fs-32px, description-fs-20px, ctaselection-asset, ctatarget-sametab, ctaexitinterstitial-select, ctatarget-sametab-two, ctaexitinterstitial-select-two, ctanumber-one
Drawing on Australian research insights, this report explores how living with overweight or obesity impacts multiple key aspects of life, including social, physical and mental wellbeing. The research was conducted by METIS Healthcare Research and commissioned by Lilly Australia.
Diagnosis to Dignity: A vision for Alzheimer’s disease in Australia
card, titleone-fs-32px, description-fs-20px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-general-third-parties, ctatarget-sametab-two, ctaexitinterstitial-select-two, ctanumber-one
An evidence-based report independently authored by Evohealth, a specialist health advisory firm, and funded by Eli Lilly Australia. The report presents a future paradigm for Alzheimer’s disease in Australia and proposes seven recommendations to support a brighter future for Australians living with Alzheimer’s disease and their careers.
Reframing Weight Management: Evolving the narrative around anti-obesity medications and prioritising care
card, titleone-fs-32px, description-fs-20px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-select, ctatarget-sametab-two, ctaexitinterstitial-select-two, ctanumber-one
This White Paper explores current obesity management in Australia and presents recommendations to transform care, disrupt disease progression and deliver breakthrough outcomes. It’s time to address misperceptions, eliminate stigma, and imagine a better future for Australians navigating this disease. This is a Lilly-commissioned White Paper developed by the life sciences consultancy firm Biointelect.
Lilly Sustainability Report
card, titleone-fs-32px, description-fs-20px, ctaselection-link, ctatarget-newtab, ctaexitinterstitial-general-third-parties, ctatarget-sametab-two, ctaexitinterstitial-select-two, ctanumber-one
Our drive to make life better for people around the world has resulted in ground-breaking discoveries and inspired global philanthropic initiatives. We are committed to driving continuous progress and improving our positive impact on people, the planet and society.